Diagnosis Gap Leaves Alzheimer's Patients Behind

Patients in the UK with Alzheimer's disease are being prevented from accessing experimental treatments due to insufficient or inaccurate diagnoses, according to Alzheimer's Research UK. This situation arises despite a record high in Alzheimer's drug trials globally this year. The charity emphasizes that a lack of timely and precise diagnoses means too few UK patients can be enrolled in these vital studies.

Dr. Sheona Scales, director of research at Alzheimer's Research UK, stated that the growing number of clinical trials increases the demand for participants. However, without a substantial and varied pool of patients to match to studies, the UK could miss out on offering its citizens access to future Alzheimer's therapies. Globally, over 32 million people live with Alzheimer's, yet obtaining a diagnosis can take years, with one in three individuals in the UK lacking a formal diagnosis.

Recent advancements include anti-amyloid medicines like lecanemab and donanemab, which have demonstrated a slight slowing of disease progression. However, the number of candidate drugs in trials has increased by 40% over the past decade, with research diversifying to target tau, inflammation, and immune system pathways. The Trailblazer-Alz 3 trial is investigating donanemab's potential to protect against cognitive decline even before symptoms appear.

Identifying suitable candidates for drug trials remains a significant obstacle. In the UK, a third of patients lack a formal diagnosis, and many existing diagnoses are too general for trial eligibility. Consequently, fewer than 1,000 UK patients are currently participating in phase 3 trials for Alzheimer's drugs. Dr. Scales reiterated that progress hinges on early and accurate diagnosis to effectively match patients with beneficial studies.